Company: INKT
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-061041
Chunk: 1

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 1
---
 stockholders entitled to vote will be open for examination by any stockholder for any purpose germane to the 2025 Annual Meeting of Stockholders for ten days before the meeting during ordinary business hours at our principal offices at 149 Fifth Avenue, Suite 500, New York, New York 10010. It is important that your shares be represented at the 2025 Annual Meeting of Stockholders. Therefore, whether or not you plan to attend the meeting virtually, please complete your proxy and return it to us. If you attend the 2025 Annual Meeting of Stockholders virtually and wish to vote at the meeting, your proxy will not be used. You may also vote your shares over the internet or by telephone. Instructions for internet or telephonic voting are printed on your proxy card.

TABLE OF CONTENTS

|                                                                                                                                                         | Page |
| GENERAL INFORMATION ABOUT OUR VIRTUAL STOCKHOLDER MEETING                                                                                               |    2 |
| VOTING PROCEDURES                                                                                                                                       |    2 |
| PROPOSAL 1—TO ELECT JENNIFER BUELL AND ULF WIINBERG AS CLASS I DIRECTORS, FOR A TERM OF THREE YEARS EXPIRING AT THE 2028 ANNUAL MEETING OF STOCKHOLDERS |    6 |
| OUR CORPORATE GOVERNANCE                                                                                                                                |   10 |
| EXECUTIVE COMPENSATION                                                                                                                                  |   14 |
| DIRECTOR COMPENSATION                                                                                                                                   |   22 |
| OWNERSHIP OF OUR COMMON STOCK                                                                                                                           |   23 |
| DELINQUENT SECTION 16(a) REPORTS                                                                                                                        |   24 |
| CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS                                                                                                          |   24 |
| PROPOSAL 2—TO APPROVE THE OPTION EXCHANGE PROPOSAL                                                                                                      |   26 |
| PROPOSAL 3—TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025      |   33 |
| REPORT OF THE AUDIT COMMITTEE                                                                                                                           |   34 |
| ADDITIONAL INFORMATION                                                                                                                                  |   35 |

<div align='center'>MiNK Therapeutics, Inc.

149 Fifth Avenue, Suite 500

New York, NY 10010

Telephone: (212) 994-8250</div>

### PROXY STATEMENT
<div align='center'>April